[
  {
    "ts": null,
    "headline": "BNY Mellon Global Equity Income Fund Q2 2025 Commentary",
    "summary": "BNY Mellon Global Equity Income Fund underperformed its benchmark index, the FTSE World Index, during the second quarter of 2025. Read more here.",
    "url": "https://finnhub.io/api/news?id=d1967e0e887970a6d5dcdb58c9d9e463c15a594900795296dd6946634ca975b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755187440,
      "headline": "BNY Mellon Global Equity Income Fund Q2 2025 Commentary",
      "id": 136351716,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171573445/image_171573445.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Global Equity Income Fund underperformed its benchmark index, the FTSE World Index, during the second quarter of 2025. Read more here.",
      "url": "https://finnhub.io/api/news?id=d1967e0e887970a6d5dcdb58c9d9e463c15a594900795296dd6946634ca975b6"
    }
  },
  {
    "ts": null,
    "headline": "Exelixis Gains 15.6% YTD: How Should You Play the Stock?",
    "summary": "EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.",
    "url": "https://finnhub.io/api/news?id=89ebbe80ffa4cba3825760fc1d1afccca49c9557883ae05049ae5714237a0246",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755177060,
      "headline": "Exelixis Gains 15.6% YTD: How Should You Play the Stock?",
      "id": 136349349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.",
      "url": "https://finnhub.io/api/news?id=89ebbe80ffa4cba3825760fc1d1afccca49c9557883ae05049ae5714237a0246"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Dynamic Value Fund Q2 2025 Commentary",
    "summary": "BNY Mellon Dynamic Value Fund (Class A at NAV) returned 5.00% during the second quarter of 2025. Read more here.",
    "url": "https://finnhub.io/api/news?id=f892debf18bb28d5f4de92b2de0ead36e77ceb9bc730d5f77257082a710ef40e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755172800,
      "headline": "BNY Mellon Dynamic Value Fund Q2 2025 Commentary",
      "id": 136348578,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344940351/image_1344940351.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Dynamic Value Fund (Class A at NAV) returned 5.00% during the second quarter of 2025. Read more here.",
      "url": "https://finnhub.io/api/news?id=f892debf18bb28d5f4de92b2de0ead36e77ceb9bc730d5f77257082a710ef40e"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends",
    "summary": "Dividend Harvesting Portfolio achieved an 8.06% profitability boost, with dividends at 19.77% of capital. Read more insights here.",
    "url": "https://finnhub.io/api/news?id=21b1268ee5c0f1315e977b251f221252a9b5674113b9142b45a444928ef7278d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755161100,
      "headline": "Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends",
      "id": 136346165,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Dividend Harvesting Portfolio achieved an 8.06% profitability boost, with dividends at 19.77% of capital. Read more insights here.",
      "url": "https://finnhub.io/api/news?id=21b1268ee5c0f1315e977b251f221252a9b5674113b9142b45a444928ef7278d"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.",
    "summary": "Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.",
    "url": "https://finnhub.io/api/news?id=7ede2251f91bf9e2d54ddb933553fa689bf92972b927da2349a5650f3035911e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755156600,
      "headline": "Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.",
      "id": 136344742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.",
      "url": "https://finnhub.io/api/news?id=7ede2251f91bf9e2d54ddb933553fa689bf92972b927da2349a5650f3035911e"
    }
  }
]